| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| JianZhong Yang, ChuanYuan Kang, Changjiang Wu, Yuanyuan Lin, Lei Zeng, Jing Yuan, Yan Zhang, YuJun Wei, Li Xu, Fang Zho. Pharmacogenetic associations of NRG1 polymorphisms with neurocognitive performance and clinical symptom response to risperidone in the untreated schizophrenia. Schizophrenia research. vol 231. 2021-07-05. PMID:33770628. |
pharmacogenetic associations of nrg1 polymorphisms with neurocognitive performance and clinical symptom response to risperidone in the untreated schizophrenia. |
2021-07-05 |
2023-08-13 |
Not clear |
| JianZhong Yang, ChuanYuan Kang, Changjiang Wu, Yuanyuan Lin, Lei Zeng, Jing Yuan, Yan Zhang, YuJun Wei, Li Xu, Fang Zho. Pharmacogenetic associations of NRG1 polymorphisms with neurocognitive performance and clinical symptom response to risperidone in the untreated schizophrenia. Schizophrenia research. vol 231. 2021-07-05. PMID:33770628. |
to explore pharmacogenetic relationships of nrg1 genotypes with neurocognitive performance and clinical symptoms after 12 week treatment of risperidone in chinese han first-episode schizophrenia. |
2021-07-05 |
2023-08-13 |
Not clear |
| Joseph Scarborough, Daniele Mattei, Cornelia Dorner-Ciossek, Michael Sand, Roberto Arban, Holger Rosenbrock, Juliet Richetto, Urs Meye. Symptomatic and preventive effects of the novel phosphodiesterase-9 inhibitor BI 409306 in an immune-mediated model of neurodevelopmental disorders. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 46. issue 8. 2021-06-28. PMID:33941860. |
in study 2, adult offspring received bi 409306 1 mg/kg and/or risperidone 0.025 mg/kg, risperidone 0.05 mg/kg, or vehicle, to evaluate bi 409306 as add-on to standard therapy for schizophrenia. |
2021-06-28 |
2023-08-13 |
mouse |
| Ryan Dammerman, Sonnie Kim, Mathews Adera, Alex Schwar. A Phase 1, Open-Label, Single Dose Pharmacokinetic Study in Stabilized Patients with Schizophrenia Following Risperidone Implant. Psychopharmacology bulletin. vol 47. issue 4. 2021-06-24. PMID:28936007. |
a phase 1, open-label, single dose pharmacokinetic study in stabilized patients with schizophrenia following risperidone implant. |
2021-06-24 |
2023-08-13 |
Not clear |
| Nian Liu, Yuan Xiao, Wenjing Zhang, Biqiu Tang, Jiaxin Zeng, Na Hu, Shah Chandan, Qiyong Gong, Su Lu. Characteristics of gray matter alterations in never-treated and treated chronic schizophrenia patients. Translational psychiatry. vol 10. issue 1. 2021-06-18. PMID:32398765. |
to explore the different patterns of gray matter alterations among chronic never treated patients and those treated with monotherapy, we recruited 35 never-treated chronic schizophrenia patients with illness durations ranging from 5 to 48 years, 20 illness duration-matched risperidone monotherapy and 20 clozapine monotherapy patients, and 55 healthy controls. |
2021-06-18 |
2023-08-13 |
Not clear |
| Sheila Garcia-Rosa, Benilton S Carvalho, Paul C Guest, Johann Steiner, Daniel Martins-de-Souz. Blood plasma proteomic modulation induced by olanzapine and risperidone in schizophrenia patients. Journal of proteomics. vol 224. 2021-06-18. PMID:32464195. |
blood plasma proteomic modulation induced by olanzapine and risperidone in schizophrenia patients. |
2021-06-18 |
2023-08-13 |
Not clear |
| Xujun Duan, Maolin Hu, Xinyue Huang, Xia Dong, Xiaofen Zong, Changchun He, Jinming Xiao, Jinsong Tang, Xiaogang Chen, Huafu Che. Effects of risperidone monotherapy on the default-mode network in antipsychotic-naïve first-episode schizophrenia: Posteromedial cortex heterogeneity and relationship with the symptom improvements. Schizophrenia research. vol 218. 2021-06-17. PMID:31954611. |
effects of risperidone monotherapy on the default-mode network in antipsychotic-naïve first-episode schizophrenia: posteromedial cortex heterogeneity and relationship with the symptom improvements. |
2021-06-17 |
2023-08-13 |
Not clear |
| Xujun Duan, Maolin Hu, Xinyue Huang, Xia Dong, Xiaofen Zong, Changchun He, Jinming Xiao, Jinsong Tang, Xiaogang Chen, Huafu Che. Effects of risperidone monotherapy on the default-mode network in antipsychotic-naïve first-episode schizophrenia: Posteromedial cortex heterogeneity and relationship with the symptom improvements. Schizophrenia research. vol 218. 2021-06-17. PMID:31954611. |
here, we conducted a longitudinal research on the resting-state functional connectivity of the pmc subdivisions on 33 treatment-naive first-episode patients with schizophrenia at baseline and after 8 weeks of risperidone treatment through resting-state functional magnetic resonance imaging. |
2021-06-17 |
2023-08-13 |
Not clear |
| Eraldo F Nicotra, Daniele Lecca, Gianluca Casu, Mario Palomba, Annesha Sil, Giorgio Marches. Lights and shadows of schizophrenia therapy research: Lessons from oral risperidone and olanzapine. Journal of psychopharmacology (Oxford, England). vol 34. issue 5. 2021-06-17. PMID:31961244. |
lights and shadows of schizophrenia therapy research: lessons from oral risperidone and olanzapine. |
2021-06-17 |
2023-08-13 |
Not clear |
| Ehsan Moazen-Zadeh, Samaneh Bayanati, Kimia Ziafat, Farzin Rezaei, Bita Mesgarpour, Shahin Akhondzade. Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial. Journal of psychopharmacology (Oxford, England). vol 34. issue 5. 2021-06-17. PMID:32122230. |
vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. |
2021-06-17 |
2023-08-13 |
Not clear |
| Kristin K Lottman, Nina V Kraguljac, David M White, Charity J Morgan, Vince D Calhoun, Allison Butt, Adrienne C Laht. Risperidone Effects on Brain Dynamic Connectivity-A Prospective Resting-State fMRI Study in Schizophrenia. Frontiers in psychiatry. vol 8. 2021-06-12. PMID:28220083. |
risperidone effects on brain dynamic connectivity-a prospective resting-state fmri study in schizophrenia. |
2021-06-12 |
2023-08-13 |
Not clear |
| Lujie Yang, Xia Q. Effect of olanzapine combined with risperidone in the treatment of schizophrenia and its influence on cognitive function. Pakistan journal of medical sciences. vol 37. issue 3. 2021-06-11. PMID:34104141. |
effect of olanzapine combined with risperidone in the treatment of schizophrenia and its influence on cognitive function. |
2021-06-11 |
2023-08-13 |
Not clear |
| Lujie Yang, Xia Q. Effect of olanzapine combined with risperidone in the treatment of schizophrenia and its influence on cognitive function. Pakistan journal of medical sciences. vol 37. issue 3. 2021-06-11. PMID:34104141. |
to explore the effect of risperidone combined with olanzapine in the treatment of schizophrenia and its influence on cognitive function. |
2021-06-11 |
2023-08-13 |
Not clear |
| Valéria de Almeida, Guilherme L Alexandrino, Adriano Aquino, Alexandre F Gomes, Michael Murgu, Henrik Dobrowolny, Paul C Guest, Johann Steiner, Daniel Martins-de-Souz. Changes in the blood plasma lipidome associated with effective or poor response to atypical antipsychotic treatments in schizophrenia patients. Progress in neuro-psychopharmacology & biological psychiatry. vol 101. 2021-06-04. PMID:32304808. |
the aim of this study was to evaluate the lipidome changes in blood plasma samples of schizophrenia patients before and after 6 weeks of treatment with either risperidone, olanzapine, or quetiapine. |
2021-06-04 |
2023-08-13 |
Not clear |
| Yuan Feng, Jianguo Shi, Lili Wang, Xia Zhang, Yunlong Tan, Jingyuan Zhao, Yuping Ning, Shiping Xie, Xuejun Liu, Qi Liu, Keqing Li, Xiaoliang Wang, Lehua Li, Xiufeng Xu, Wei Deng, Xiaoyan Luo, Gang Wan. Randomized, double-blind, 6-week non-inferiority study of lurasidone and risperidone for the treatment of schizophrenia. Psychiatry and clinical neurosciences. vol 74. issue 6. 2021-05-31. PMID:31823444. |
randomized, double-blind, 6-week non-inferiority study of lurasidone and risperidone for the treatment of schizophrenia. |
2021-05-31 |
2023-08-13 |
Not clear |
| Philip D Harvey, Hiroshi Nakamura, Sadanori Miur. Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study. Neuropsychopharmacology reports. vol 40. issue 1. 2021-05-28. PMID:31788985. |
blonanserin vs risperidone in japanese patients with schizophrenia: a post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study. |
2021-05-28 |
2023-08-13 |
Not clear |
| Philip D Harvey, Hiroshi Nakamura, Sadanori Miur. Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study. Neuropsychopharmacology reports. vol 40. issue 1. 2021-05-28. PMID:31788985. |
to report the efficacy and safety of blonanserin in patients with schizophrenia compared with risperidone in a japanese multicenter, randomized, double-blind study based on post hoc sensitivity analysis in addition to the previous results reported by miura and discuss the current approaches for schizophrenia treatment. |
2021-05-28 |
2023-08-13 |
Not clear |
| Yi Chen, Yaoyao Zhang, Kaili Fan, Weiqian Xu, Chao Teng, Shuangshuang Wang, Wei Tang, Xiaomin Zh. Association between gonadal hormones and osteoporosis in schizophrenia patients undergoing risperidone monotherapy: a cross-sectional study. PeerJ. vol 9. 2021-05-16. PMID:33987015. |
association between gonadal hormones and osteoporosis in schizophrenia patients undergoing risperidone monotherapy: a cross-sectional study. |
2021-05-16 |
2023-08-13 |
Not clear |
| Xujun Duan, Maolin Hu, Xinyue Huang, Chan Su, Xiaofen Zong, Xia Dong, Changchun He, Jinming Xiao, Haoru Li, Jinsong Tang, Xiaogang Chen, Huafu Che. Effect of Risperidone Monotherapy on Dynamic Functional Connectivity of Insular Subdivisions in Treatment-Naive, First-Episode Schizophrenia. Schizophrenia bulletin. vol 46. issue 3. 2021-05-14. PMID:31504959. |
effect of risperidone monotherapy on dynamic functional connectivity of insular subdivisions in treatment-naive, first-episode schizophrenia. |
2021-05-14 |
2023-08-13 |
Not clear |
| Xue Li, Xiuxia Yuan, Yulin Kang, Lijuan Pang, Yafei Liu, Qiyue Zhu, Luxian Lv, Xu-Feng Huang, Xueqin Son. A synergistic effect between family intervention and rTMS improves cognitive and negative symptoms in schizophrenia: A randomized controlled trial. Journal of psychiatric research. vol 126. 2021-05-14. PMID:32428747. |
the present study explored an efficient new therapy that combined repetitive transcranial magnetic stimulation (rtms) and family intervention in addition to risperidone to improve schizophrenia. |
2021-05-14 |
2023-08-13 |
Not clear |